The Novel MFG-E8-derived Oligopeptide, MOP3, Improves Outcomes in a Preclinical Murine Model of Neonatal Sepsis

This preclinical study investigates MOP3, a novel oligopeptide derived from MFG-E8, as a therapeutic agent for neonatal sepsis. The research demonstrates MOP3's mechanism of clearing pro-inflammatory eCIRP to reduce inflammation, organ injury, and mortality in murine models of neonatal sepsis.